Clinical trials: CIN
Cervical Intraepithelial Neoplasia
Physical Cold Atmospheric Plasma for the Treatment of Cervical Intraepithelial Neoplasia
Cervical intraepithelial neoplasia will be treated with physical low temperature plasma in the plasma cohort compared to watchful waiting in the control cohort. Primary endpoint after 3-6 months: Pathological remission.
- Trial name
- CAPCIN (NCT03218436)
- Testing
- CAP treatment
- Where
- Germany
- Volunteers
- 63 people
- Sponsor
- University Hospital Tuebingen
Uterine Cervical Neoplasm, Uterine Cervical Dysplasia
Developing a Combined Molecular Screening and Triage Test for Cervical Cancer in Self-samples
The goal of the COMBISCREEN project is to develop a fully molecular cervical screening and triage approach that is applicable on self-samples, which are an easily accessible and non-invasive source of biomarkers.
- Conditions
- Uterine Cervical Neoplasm, Uterine Cervical Dysplasia, Human Papilloma Virus, HPV-Related Cervical Carcinoma
- Trial name
- COMBISCREEN (NCT06598176)
- Testing
- Colli-Pee 20mL device with UCM, Evalyn Brush
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Universiteit Antwerpen
Human Papilloma Virus, Cervical Dysplasia
Educational Video's Impact on Knowledge Regarding Cervical Cancer Screening
The researchers will be conducting a prospective randomized trial where the researchers will be introducing an educational video to see whether there is an increase in knowledge scores surrounding cervical cancer, cervical cancer…
- Trial name
- NCT05756192
- Testing
- Educational video
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- George Washington University
Cervical Cancer
Mobile High-Resolution Microendoscopy (mHRME) for the Detection of Cervical Dysplasia in El Salvador
Evaluate the performance of the mHRME in a study of 3,000 women in San Salvador to assess whether mHRME imaging improves specificity of screening by VIA or HPV DNA without reducing sensitivity for cervical precancer and cancer.
- Trial name
- NCT04472455
- Testing
- HRME
- Volunteers
- 1,827 people, healthy volunteers welcome
- Sponsor
- William Marsh Rice University
Cervical Cancer Screening, Human Papilloma Virus (HPV)
HPV Testing as a Prevention of Cervical Dysplasia and Cancer Before Planned Subtotal Hysterectomy
Patients indicated for subtotal hysterectomy will be tested for High risk HPV and if the result is positive will undergo expert colposcopy and conisation if not indicated otherwise at the time of subtotal hysterectomy
- Trial name
- NCT07545525
- Volunteers
- 300 people
- Sponsor
- General University Hospital, Prague
HIV/AIDS, Cervical Dysplasia
Factors Predicting Persistence of Oncogenic HPV and Cervical Dysplasia in HIV Infected Kenyan Women
This study will utilize a longitudinal study design to better understand the natural history of oncogenic Human Papillomavirus (HPV) infections in Human Immunodeficiency Virus (HIV)-infected and HIV-uninfected Kenyan women…
- Conditions
- HIV/AIDS, Cervical Dysplasia, HIV Infections
- Trial name
- NCT04045652
- Where
- 3 sites in United States, Kenya and 1 more
- Volunteers
- 223 people
- Sponsor
- Indiana University
Malignant Neoplasms of Female Genital Organs
Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley
The purpose of this study is to evaluate a different type of medical equipment called "High-Resolution Microendoscope" (HRME) for the diagnosis of cervical pre-cancerous lesions and cervical cancer.
- Trial name
- NCT02714439
- Testing
- Proflavine, High-Resolution Microendoscopy (HRME)
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Precancerous Condition
Activating Collaborative CIS Support Via Targeted Provider Mailing
RATIONALE: Receiving a reminder letter from their doctor with questions to ask the Cancer Information Service may be more effective than a standard reminder letter in helping patients who have had an abnormal Pap test keep their…
- Trial name
- NCT00873288
- Testing
- Usual care mailing intervention, CIS support mailing intervention
- Where
- 2 sites in United States
- Volunteers
- 254 people
- Sponsor
- Northwestern University
Cervical Cancer, Cervical Intraepithelial Neoplasia
PRIORITY Study in Cervical Cancer
The PRIORITY study is a prospective, multicenter observational study designed to evaluate an integrated diagnostic model combining extended molecular self-sampling and digital colposcopy supported by telemedicine for the…
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia, HPV Infection
- Trial name
- PRIORITY (NCT07593066)
- Where
- 8 sites in Chile
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Pontificia Universidad Catolica de Chile
Cervical Intraepithelial Neoplasia Grade 2 (CIN2)
RWS of PDT for CIN 2
This is a prospective, observational, multicenter real-world study designed to evaluate the effectiveness and safety of photodynamic therapy (PDT) in women with cervical intraepithelial neoplasia grade 2 (CIN2).
- Trial name
- Lumiteg-R (NCT07885566)
- Testing
- Hexaminolevulinate (HAL)
- Volunteers
- 1,000 people
- Sponsor
- Tongji Hospital
Papillomavirus Infections
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.
The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.
- Trial name
- NCT00312286
- Testing
- 851B
- Where
- 93 sites in United States, Canada and 1 more
- Volunteers
- 538 people
- Sponsor
- Takeda
Cervical Cancer, Precancerous Condition
Study of Pap Smears From Patients Enrolled on Clinical Trial GOG-171
RATIONALE: Studying Pap smears in the laboratory from women with atypical glandular cells of unspecified significance may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898144
- Testing
- Papanicolaou test, laboratory biomarker analysis
- Volunteers
- 55 people
- Sponsor
- Gynecologic Oncology Group
Contrast Induced Nephropathy (CIN)
AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN
The Osprey Medical AVERT System is indicated to reduce contrast media (CM) exposure to the kidneys during percutaneous coronary procedures thereby reducing the risk of contrast induced nephropathy (CIN).
- Trial name
- AVERT™ (NCT01976299)
- Testing
- AVERT
- Where
- 39 sites in United States, Australia and 1 more
- Volunteers
- 578 people
- Sponsor
- Osprey Medical, Inc
HPV Disease, Cervical Intraepithelial Neoplasia Grade I
HIFU vs Observation for LSIL of Cervix: A Randomized Controlled Trial
The majority of low-grade pre-invasive lesions of cervix (low-grade squamous intraepithelial lesions, LSIL).will regress spontaneously over 2 years and immediate treatment may not be necessary.
- Trial name
- HIFU Colpo (NCT07461064)
- Testing
- HIFU treatment
- Volunteers
- 180 people
- Sponsor
- Queen Mary Hospital, Hong Kong
Cervical Intraepithelial Neoplasia
An Innovative Treatment for Cervical Precancer (UH3)
The purpose of this academic-industrial partnership will compare the CryoPen® and thermoablator to traditional CO2-based cryotherapy for the treatment of cervical precancer in low and middle income countries (LMICs) and…
- Trial name
- UH3 (NCT03084081)
- Testing
- CO2 standard therapy, CryoPen, Thermocoagulator
- Where
- 3 sites in China, Colombia and 1 more
- Volunteers
- 1,132 people
- Sponsor
- The Cleveland Clinic
Radiographic Contrast Agent Nephropathy
Relationship Between ALDH2 and CIN
The purpose of this clinical trial is to investigate the relationship between the gene polymorphism of aldehyde dehydrogenase 2 and contrast induced nephropathy and its mechanism.
- Trial name
- REACTION (NCT02643706)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Qilu Hospital of Shandong University
Cervical Intraepithelial Neoplasia Grade 1, Cervical Intraepithelial Neoplasia Grade 2
Colposcopy and High Resolution Anoscopy in Screening For Anal Dysplasia in Patients With Cervical, Vaginal, or Vulvar Dysplasia or Cancer
This clinical trial studies colposcopy and high resolution anoscopy in screening for anal dysplasia in patients with cervical, vaginal, or vulvar dysplasia or cancer.
- Conditions
- Cervical Intraepithelial Neoplasia Grade 1, Cervical Intraepithelial Neoplasia Grade 2, Cervical Intraepithelial Neoplasia Grade 3, Recurrent Cervical Cancer
- Trial name
- NCT01313104
- Testing
- colposcopy, cervical Papanicolaou test, screening method
- Sponsor
- Northwestern University
Uterine Cervical Dysplasia, Papillomavirus Infections
Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix
1. Introduction Cervical cancer (CC) is a major public health problem in Low-income countries (LICs), particularly in the Democratic Republic of the Congo (DRC), where the estimated number of cases is 3839 per year. (WHO, 2010).
- Trial name
- KINVAV (NCT02346227)
- Testing
- AV2
- Where
- Democratic Republic of the Congo
- Volunteers
- 327 people, healthy volunteers welcome
- Sponsor
- Jean-Pierre Van geertruyden
CIN, Cervical Cancer
New Gentle Biopsy Method of Cervix Lesions Using Superficial Curettage/Protocol ID: CX-CUR
It is to investigate to what extent a gentle tissue extraction of CIN lesions of the cervix will bring the same conclusion than the conventional cervix biopsy, but with less pain and morbidity, after patients were undergoing a…
- Trial name
- NCT01836588
- Testing
- conventional cervix biopsy
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- Charite University, Berlin, Germany
Cervical Intraepithelial Neoplasia
A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects
The purpose of this prospective, multi-centre, PMS cohort study was to monitor the safety of Cervarix, which is the first HPV vaccine licensed for use in China, to help prevent cervical cancer caused by HPV types 16 and 18.
- Trial name
- NCT03438006
- Testing
- Safety data collection (following routine vaccination)
- Where
- 7 sites in China
- Volunteers
- 3,016 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline